Oncology and Hematology - Global Oncology Academy

113-128 of 157

Emerging immunotherapy combination strategies in genitourinary malignancies
Emerging immunotherapy combination strategies in genitourinary malignancies
MinuteCE®
Emerging immunotherapy combination strategies in genitourinary malignancies
1.25 program credits
- Sandy Srinivas, MD
1.25 program credits
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
MinuteCE®
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
1.25 program credits
- Ignacio Duran, MD
- Wenxin Xu, MD
1.25 program credits
Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
MinuteCE®
Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
1.00 program credit
- Susana Campos, MD, MPH
- Ritu Salani, MD, MBA
1.00 program credit
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
MinuteCE®
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
1.00 program credit
- Nicoletta Colombo, MD
- Susana Campos, MD, MPH
1.00 program credit
Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer
Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer
MinuteCE®
Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer
1.00 program credit
- Ritu Salani, MD, MBA
- Susana Campos, MD, MPH
1.00 program credit
First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
MinuteCE®
First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
1.00 program credit
- Nicoletta Colombo, MD
- Ritu Salani, MD, MBA
1.00 program credit
Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
MinuteCE®
Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
1.00 program credit
- Ritu Salani, MD, MBA
- Nicoletta Colombo, MD
1.00 program credit
Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
MinuteCE®
Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
1.00 program credit
- Susana Campos, MD, MPH
- Ritu Salani, MD, MBA
1.00 program credit
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
MinuteCE®
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
1.00 program credit
- Ritu Salani, MD, MBA
- Nicoletta Colombo, MD
1.00 program credit
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
MinuteCE®
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
1.00 program credit
- Susana Campos, MD, MPH
1.00 program credit
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
MinuteCE®
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
1.00 program credit
- Nicoletta Colombo, MD
1.00 program credit
Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
MinuteCE®
Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
1.00 program credit
- Susana Campos, MD, MPH
- Nicoletta Colombo, MD
1.00 program credit
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Lung Cancer
1.00 credit 10 episodes
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 credit 10 episodes
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
MinuteCE®
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
MinuteCE®
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
MinuteCE®
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit

8/8